A citation-based method for searching scientific literature


List of co-cited articles
15 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


SGLT inhibitor adjunct therapy in type 1 diabetes.
Rory J McCrimmon, Robert R Henry. Diabetologia 2018
28
50


The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
227
33

Grading quality of evidence and strength of recommendations.
David Atkins, Dana Best, Peter A Briss, Martin Eccles, Yngve Falck-Ytter, Signe Flottorp, Gordon H Guyatt, Robin T Harbour, Margaret C Haugh, David Henry,[...]. BMJ 2004
33

Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.
Bruce A Perkins, David Z I Cherney, Helen Partridge, Nima Soleymanlou, Holly Tschirhart, Bernard Zinman, Nora M Fagan, Stefan Kaspers, Hans-Juergen Woerle, Uli C Broedl,[...]. Diabetes Care 2014
144
33

Quality of life and type 1 diabetes: a study assessing patients' perceptions and self-management needs.
Dácil Alvarado-Martel, Rebeca Velasco, Rosa M Sánchez-Hernández, Armando Carrillo, Francisco Javier Nóvoa, Ana María Wägner.  2015
9
33

Sodium glucose cotransporters inhibitors in type 1 diabetes.
Sergio Dellepiane, Moufida Ben Nasr, Emma Assi, Vera Usuelli, Teresa Letizia, Francesca D'Addio, Gian Vincenzo Zuccotti, Paolo Fiorina. Pharmacol. Res. 2018
5
40

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
113
33


Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes.
Bruce A Perkins, David Z I Cherney, Nima Soleymanlou, Justin A Lee, Helen Partridge, Holly Tschirhart, Bernard Zinman, Roger Mazze, Nora Fagan, Stefan Kaspers,[...]. PLoS ONE 2015
22
33

Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus.
Mojca Lunder, Miodrag Janić, Miha Japelj, Andrej Juretič, Andrej Janež, Mišo Šabovič. Cardiovasc Diabetol 2018
16
33

Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type-2 Diabetes.
Uche Anadu Ndefo, Nicole O Anidiobi, Efrah Basheer, Angie T Eaton.  2015
7
33



2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur. Heart J. 2020
303
33

Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations.
Chaicharn Deerochanawong, Siew P Chan, Bien J Matawaran, Wayne H-H Sheu, Juliana Chan, Nguyen H Man, Ketut Suastika, Chin M Khoo, Kun-Ho Yoon, Andrea Luk,[...]. Diabetes Obes Metab 2019
8
16

Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
Thomas Danne, Bertrand Cariou, John B Buse, Satish K Garg, Julio Rosenstock, Phillip Banks, Jake A Kushner, Darren K McGuire, Anne L Peters, Sangeeta Sawhney,[...]. Diabetes Care 2019
19
16

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
68
16

Impact of severe and symptomatic hypoglycemia on quality of life and fear of hypoglycemia in type 1 and type 2 diabetes. Results of the Hypos-1 observational study.
Maria Chiara Rossi, Antonio Nicolucci, Alessandro Ozzello, Sandro Gentile, Alberto Aglialoro, Anna Chiambretti, Fabio Baccetti, Francesco M Gentile, Francesco Romeo, Giuseppe Lucisano,[...]. Nutr Metab Cardiovasc Dis 2019
6
16


Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
Thomas Danne, Torben Biester, Olga Kordonouri. Diabetes Technol. Ther. 2018
14
16

Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component?
Francesco Prattichizzo, Valeria De Nigris, Stefano Micheloni, Lucia La Sala, Antonio Ceriello. Diabetes Obes Metab 2018
29
16

Sotagliflozin: First Global Approval.
Anthony Markham, Susan J Keam. Drugs 2019
10
16

Sustained Reduction in Severe Hypoglycemia in Adults With Type 1 Diabetes Complicated by Impaired Awareness of Hypoglycemia: Two-Year Follow-up in the HypoCOMPaSS Randomized Clinical Trial.
Stuart A Little, Jane Speight, Lalantha Leelarathna, Emma Walkinshaw, Horng Kai Tan, Anita Bowes, Alexandra Lubina-Solomon, Thomas J Chadwick, Deborah D Stocken, Catherine Brennand,[...]. Diabetes Care 2018
15
16

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi, Andrea Giaccari. Cardiovasc Diabetol 2019
18
16

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.
Gordon H Guyatt, Andrew D Oxman, Gunn E Vist, Regina Kunz, Yngve Falck-Ytter, Pablo Alonso-Coello, Holger J Schünemann. BMJ 2008
16

Hypoglycemia, chronic kidney disease, and diabetes mellitus.
Mazen Alsahli, John E Gerich. Mayo Clin. Proc. 2014
23
16

The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes.
Yan-Ling He, William Haynes, Charles D Meyers, Ahmed Amer, Yiming Zhang, Ping Mahling, Anisha E Mendonza, Shenglin Ma, William Chutkow, Eric Bachman. Diabetes Obes Metab 2019
16
16

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann. Intern. Med. 2013
420
16

HbA1c and monitoring glycaemia.
Patrick J Phillips. Aust Fam Physician 2012
5
20

Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
Akira Shimada, Toshiaki Hanafusa, Atsutaka Yasui, Ganghyuck Lee, Yusuke Taneda, Akiko Sarashina, Kosuke Shiki, Jyothis George, Nima Soleymanlou, Jan Marquard. Diabetes Obes Metab 2018
10
16


Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
533
16

Power failure: why small sample size undermines the reliability of neuroscience.
Katherine S Button, John P A Ioannidis, Claire Mokrysz, Brian A Nosek, Jonathan Flint, Emma S J Robinson, Marcus R Munafò. Nat. Rev. Neurosci. 2013
16


Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
T R Pieber, S Famulla, J Eilbracht, J Cescutti, N Soleymanlou, O E Johansen, H J Woerle, U C Broedl, S Kaspers. Diabetes Obes Metab 2015
84
16

How meta-analysis increases statistical power.
Lawrence D Cohn, Betsy J Becker. Psychol Methods 2003
188
16

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.
Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra Green, Afshin Salsali, Uli C Broedl, Hans J Woerle. Diabetes Care 2015
222
16

Measuring inconsistency in meta-analyses.
Julian P T Higgins, Simon G Thompson, Jonathan J Deeks, Douglas G Altman. BMJ 2003
16

Single-center trials tend to provide larger treatment effects than multicenter trials: a systematic review.
Susanne Unverzagt, Roland Prondzinsky, Frank Peinemann. J Clin Epidemiol 2013
33
16

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N. Engl. J. Med. 2017
139
16

Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
Gianluigi Savarese, Carmen D'Amore, Massimo Federici, Fabiana De Martino, Santo Dellegrottaglie, Caterina Marciano, Francesca Ferrazzano, Teresa Losco, Lars H Lund, Bruno Trimarco,[...]. Int. J. Cardiol. 2016
37
16

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
Alessandro Liberati, Douglas G Altman, Jennifer Tetzlaff, Cynthia Mulrow, Peter C Gøtzsche, John P A Ioannidis, Mike Clarke, P J Devereaux, Jos Kleijnen, David Moher. J Clin Epidemiol 2009
16

Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
John Mondick, Matthew Riggs, Stefan Kaspers, Nima Soleymanlou, Jan Marquard, Valerie Nock. J Clin Pharmacol 2018
4
25


SGLT-2 Inhibitors: Is There a Role in Type 1 Diabetes Mellitus Management?
Nabila Ahmed-Sarwar, Angela K Nagel, Samantha Leistman, Kevin Heacock. Ann Pharmacother 2017
6
16


Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1).
Susanne Famulla, Thomas R Pieber, Jens Eilbracht, Dietmar Neubacher, Nima Soleymanlou, Hans J Woerle, Uli C Broedl, Stefan Kaspers. Diabetes Technol. Ther. 2017
22
16




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.